GLP-1 weight loss plateaus: panic, physiology, or both?

What did @harry_glp1 actually say?

The claim is specific: the most dangerous moment on a GLP-1 medication is when weight loss slows down. He argues that people misread a plateau as failure, then "break something that was actually working" by stopping or changing course too soon. That's a behavioral argument, not a pharmacological one, and it's worth separating those two things before agreeing or disagreeing with it.

To be fair, he's not making a wild fringe claim. He's pointing at a real, documented pattern in medication adherence. The framing is punchy and a little dramatic, but the core observation is grounded in something clinicians actually see. Whether "dangerous" is the right word is debatable, but the behavioral trap he's describing is real.

Does the science back this up?

Yes, mostly. Weight loss plateaus on GLP-1 receptor agonists are well-documented and frequently misunderstood by patients. The idea that slowing weight loss signals a broken treatment is a misconception that does lead to early discontinuation, and early discontinuation does have consequences.

A 2022 trial by Wilding et al. in Diabetes, Obesity and Metabolism showed that patients who stopped semaglutide regained two-thirds of their lost weight within a year. That's a significant finding. It suggests continuing the medication even during slower phases matters. Separately, a 2023 analysis by Wadden et al. in Obesity found that weight loss on semaglutide typically plateaus around 60-65 weeks, but that doesn't mean the drug has stopped working metabolically. Patients who stayed on the medication maintained their losses; those who stopped did not. The plateau is a normal pharmacological event, not a sign of drug failure.

What did they get wrong (or right)?

He got the behavioral insight right. The plateau-as-failure misread is a real phenomenon, and the downstream consequence, stopping a medication that was still doing its job, is something clinicians consistently report. Credit where it's due.

Where the framing gets slippery is the word "dangerous." Stopping a GLP-1 early is suboptimal, and the weight regain data is concerning, but calling a plateau "the most dangerous moment" is rhetorical escalation. There are genuinely dangerous moments on GLP-1 therapy: unmanaged pancreatitis symptoms, severe gastroparesis, or drug interactions that get ignored. A patient misreading a plateau and pausing treatment is a problem, but ranking it above those is questionable.

He also glosses over why people stop. It isn't always psychology. Cost, side effects, and access issues drive a lot of discontinuation. Framing early stopping primarily as a cognitive error lets the structural problems off the hook.

What should you actually know?

Plateaus on GLP-1 medications are expected, not exceptional. The body adapts its energy expenditure as weight drops, which means the same dose produces slower results over time. That's physiology, not failure. A plateau typically does not mean the medication has stopped working; it often means it is doing exactly what it should at a new metabolic set point.

If your weight loss has stalled, the right response is a conversation with your prescriber, not self-directed changes. Dose adjustments, timing, and dietary patterns all interact with how these medications perform. What looks like a plateau might also reflect a behavioral drift that a clinician can help identify. And critically, stopping the medication without medical guidance and then restarting carries its own risks and costs. The data on weight regain after stopping is stark enough that it deserves to be part of any conversation about pausing treatment.

• Plateaus typically appear around week 60-65 on semaglutide, per published trial data.
• Two-thirds of lost weight returns within a year of stopping, based on Wilding et al. 2022.
• Discontinuation is often structural, driven by cost and access, not just psychology.
• A plateau does not require a dose change without clinical input.